The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback